NeuroSense Therapeutics Ltd. (NRSN) Key Metrics
NRSN valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $5.8M
- Enterprise value
- $13.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 2.6 10-yr median 3.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.64
NRSN key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNRSN valuation Price multiples at each fiscal year-end price.
Free cash flow yield+6.3 pts
−39.1%
2025 · hover or tap a bar for each year
20192025
NRSN returns How much profit the business earns on the capital it uses.
Return on assets−134.0 pts
−397.1%
2025 · hover or tap a bar for each year
20192025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20192025
NRSN per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20192025
Earnings per share
−$8.73
2025 · hover or tap a bar for each year
20192025
Free cash flow per share
−$6.03
2025 · hover or tap a bar for each year
20192025
Book value per share
−$1.22
2025 · hover or tap a bar for each year
20192025
Shares outstanding+37.0%
1.3M
2025 · hover or tap a bar for each year
20192025
NRSN financial health Debt, liquidity and how easily interest is covered.
Net debt+$3.3M
$4,000
2025 · hover or tap a bar for each year
20192025
Current ratio−86.0%
0.31
2025 · hover or tap a bar for each year
20192025
Debt / assets+936.4%
0.17
2025 · hover or tap a bar for each year
20192025
NRSN valuation history
Fiscal year-endToday7-year median
NRSN returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NRSN debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NRSN price vs earnings per share
Share price at year-endEPS (right axis)
NRSN key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $19.6M | $22.3M | $10.7M | $14.0M | $26.7M | — | — |
| Enterprise value | $19.6M | $19.0M | $8.2M | $7.2M | $17.5M | — | — |
| Price / book | — | 8.6 | — | 2.5 | 3.0 | — | — |
| Earnings yield | −56.7% | −45.7% | −94.3% | −87.9% | −15.1% | — | — |
| Free cash flow yield | −39.1% | −45.4% | −78.2% | −54.5% | −5.8% | — | — |
| Share price at fiscal year-end | $15.40 | $24.00 | $15.72 | $24.40 | $49.20 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Earnings per share | −$8.73 | −$10.98 | −$14.82 | −$21.45 | −$7.44 | — | — |
| Operating cash flow per share | −$6.02 | −$10.90 | −$12.25 | −$13.19 | −$2.84 | — | — |
| Free cash flow per share | −$6.03 | −$10.90 | −$12.29 | −$13.31 | −$2.87 | — | — |
| Cash per share | $0.13 | $3.63 | $3.87 | $12.33 | $20.38 | — | — |
| Book value per share | −$1.22 | $2.78 | −$2.58 | $9.77 | $16.59 | — | — |
| Tangible book value per share | −$1.22 | $2.78 | −$2.58 | $9.77 | $16.59 | — | — |
| Capex per share | $0.01 | $0.00 | $0.04 | $0.12 | $0.03 | — | — |
| Debt per share | $0.13 | $0.08 | $0.21 | $0.37 | $3.37 | — | — |
| Shares outstanding | 1.3M | 930K | 682K | 575K | 543K | — | — |
| Change in shares outstanding | +37.0% | +36.4% | +18.6% | +6.0% | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | — | — | — | −168.8% | −83.6% | −358.7% | −133.7% |
| Return on assets (ROA) | −397.1% | −263.1% | −185.5% | −128.9% | −66.2% | −326.2% | −128.5% |
| Return on tangible assets | — | −223.2% | −317.3% | −160.1% | −35.4% | −363.0% | −128.5% |
| Financial health | |||||||
| Total debt | $170,000 | $73,000 | $142,000 | $211,000 | $1.8M | — | — |
| Cash & short-term investments | $166,000 | $3.4M | $2.6M | $7.1M | $11.1M | $699,000 | $895,000 |
| Net debt | $4,000 | −$3.3M | −$2.5M | −$6.9M | −$9.2M | −$699,000 | −$895,000 |
| Debt / equity | — | 0.03 | — | 0.04 | 0.20 | — | — |
| Debt / assets | 0.17 | 0.02 | 0.04 | 0.03 | 0.16 | — | — |
| Current ratio | 0.31 | 2.21 | 0.84 | 4.28 | 19.12 | 6.08 | 24.68 |
| Quick ratio | 0.31 | 2.21 | 0.84 | 6.41 | 19.41 | 6.08 | 24.68 |
| Interest coverage | — | -31.8 | -21.9 | -903.5 | -4.8 | — | -247.0 |
| Working capital | −$1.7M | $2.4M | −$543,000 | $5.7M | $10.8M | $609,000 | $876,000 |
| Invested capital | −$1.6M | −$722,000 | −$4.3M | −$1.3M | −$229,000 | −$40,000 | $23,000 |
| Tangible asset value | −$1.6M | $2.6M | −$1.8M | $5.6M | $9.0M | $659,000 | $918,000 |
| Net current asset value | −$1.8M | $2.4M | −$2.0M | $5.3M | $9.0M | $609,000 | $876,000 |
| Graham net-net per share | −$1.88 | $1.62 | −$3.20 | $5.66 | $16.00 | — | — |
| Capital allocation | |||||||
| Capex / depreciation | 0.50 | 0.14 | 1.38 | 0.79 | 5.67 | 3.00 | 2.33 |
| Efficiency | |||||||
| Days of inventory on hand | — | — | — | -7,907.0 | -10,832.4 | -5.2 | — |
| Days payables outstanding | — | 21,725.8 | 3,682.0 | 1,101.2 | 5,718.3 | 4,745.0 | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | — | 0.02 | 0.10 | 0.33 | 0.06 | 0.08 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $98,500 | $165,000 | $148,500 | $154,500 | $104,000 | $24,000 | $18,000 |
| Average payables | $979,500 | $1.3M | $978,500 | $268,500 | $47,000 | $39,000 | $23,000 |
| Average inventory | — | — | — | −$1.9M | −$89,034 | −$42 | −$18 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from NRSN's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NRSN valuation and financial ratios
It ended the year with $0.2 million of debt and $0.2 million in cash and short-term investments, net debt of $0.0 million.
See the NRSN income statement, the NRSN chart for price history, or the NRSN stock overview for the latest quote and news.
NRSN key metrics FAQ
How much debt does NeuroSense Therapeutics have?
NeuroSense Therapeutics had total debt of $0.2 million at the end of fiscal 2025.
What is NeuroSense Therapeutics's free cash flow yield?
NeuroSense Therapeutics generated -$7.7 million of free cash flow in fiscal 2025, a free cash flow yield of −39.1% on its market value at year-end ($19.6 million).
What is NeuroSense Therapeutics's current ratio?
NeuroSense Therapeutics's current ratio was 0.31 at the end of fiscal 2025: current assets were 0.31 times current liabilities.